DYN

Dyne Therapeutics, Inc. (DYN) | Rumor.io

Dyne Therapeutics

DYN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,054

Bullish sentiment (50-day avg)17%

Price to earnings ratio-4.71

Market capitalization3.1B

Earnings per share-3.26

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-446.2M

Social

What share of all stock conversation is about DYN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Sep 9

Dyne Therapeutics' (DYN) stock fell 16% after Novartis' del-desiran failed to meet its primary endpoint in a Phase 3 trial for myotonic dystrophy type 1 (DM1).
The failure raises questions about the clinical efficacy of DYN's z-basivarsen, which uses a similar RNA-targeting approach.
Analysts have maintained their buy ratings for DYN, with some even seeing the drop as an opportunity, citing its upcoming PDUFA date on January 21, 2027, for its BLA in exon 51 DMD.

Generated by AI

Sentiment

Of the messages about DYN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	17.36%	81.95% +7.34
Bearish	0%	0%	82.64%	18.05% -7.34

Bullish· Mar 10

$DYN's positive 24-month cardiopulmonary data from the DELIVER trial reinforces its efficacy and safety profile, and the initiation of the Phase 3 HARMONIA trial is a significant step toward confirmatory approval.
The initiation of the Phase 3 HARMONIA trial for Myotonic Dystrophy Type 1 could push $DYN's price above $20, with a target price of $36-$39.
$DYN's breakout on price and OBV after announcing the initiation of the Phase 3 trial for Myotonic Dystrophy Type 1 is a strong indication of active repositioning and could lead to a crowded trade if the breakout confirms.

Bearish· Sep 3

$DYN's poor Phase 1/2 results led to a 30% stock price drop, and the company's lack of annual revenue raises concerns about the drug's viability.
The company's management team change and recent insider selling activity, including the Board and senior management selling shares in August, may indicate that the results were worse than expected.
$DYN's stock price has been volatile, with a significant decline, and some investors are questioning whether the price will continue to fall, potentially reaching single digits by the end of the year.

Generated by AI

Topics

Of the messages about DYN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	11.72%	77.93%
Technical Analysis	100%	100%	1.67%	3.62%
Analysts	0%	0%	43.51%	12%
Controversies	0%	0%	0%	0.14%
Macro	0%	0%	43.1%	6.31%
Earnings	0%	0%	0%	0%

Earnings· Nov 1

$DYN misses Estimize EPS consensus by 26c and beats revenue consensus by $32.26M.
$DYN reports FQ3 earnings of 23c EPS and $1.44B Revs.
$DYN reports Q3 EPS loss of $0.89, missing consensus by $0.29.

Announcements· Dec 8

Dyne Therapeutics ($DYN) plans to file for approval for a next-generation Duchenne drug, potentially a more effective version of Sarepta's Exondys.
The company announced positive topline results from the Phase 1/2 DELIVER trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD).
Dyne Therapeutics has announced a proposed public offering of common stock, with the company planning to sell $300 million worth of new shares.

Technical Analysis· Jan 3

$DYN has reached an all-time high (ATH) and is approaching it, with a target above $30.
A trend line on $DYN is cracking, indicating a potential short opportunity, with possible targets at $25-26 and $29-30.
$DYN's price action is showing a possible short setup below $17.5, with a potential long opportunity above $24.00, and a low float of 31.4 million shares.

Generated by AI

Community

Of the messages about DYN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	17.03%	50.83%
Newcomers	100%	100%	82.97%	49.17%

Regulars· Sep 8

The main topic of discussion among regulars is the efficacy of Dyne Therapeutics' (DYN) z-basivarsen in correcting DM1 by reducing toxic DMPK RNA, with some comparing it to a rival drug from Spark Therapeutics (SRPT).
Regulars are closely following the upcoming milestones for DYN, including the PDUFA date for z-rostudirsen in DMD, the potential submission for US approval of z-basivarsen, and the expected launch of z-rostudirsen in the US.
The recent sell-off of DYN stock is attributed to the failure of a rival drug, and regulars are debating the potential for DYN to overcome the challenges of dosing high enough to achieve significant knockdown of DMPK RNA.

Newcomers· Sep 8

New investors are focusing on the potential of Dyne Therapeutics, Inc. (DYN) as a treatment option, specifically the operating mechanism of its ASOs in the nucleus compared to other treatments.
Some newcomers are trying to gauge the market's sentiment towards DYN, comparing its performance to that of another company, Spark Therapeutics (SRPT), and looking for specific price levels to be reached in order to re-rate the stock.
A few newcomers are looking for news or explanations behind the recent price drop of DYN, with some questioning the reason behind the 30% decline and others expressing skepticism or frustration.

Generated by AI

News

Dyne Therapeutics stock rises on positive DM1 trial results

14h agoYahoo Finance

Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence

21h agoInvesting.com

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity

12d agoYahoo! Finance Canada

Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?

Dyne Therapeutics announced it will present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 at upcoming World Muscle Society and AANEM meetings in late September and early October 2026. The breadth of new functional and safety data, alongside details from a matched natural history cohort and a fully enrolled registrational expansion cohort, adds depth to Dyne’s emerging clinical story in DM1. We’ll now examine how...

12d agoYahoo Finance

Dyne Therapeutics at Morgan Stanley conference: launch plans take focus

16d agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)

Tipranks Press Release.

18d agoThe Globe and Mail

Also Discussed

Investors talking about DYN also mention

#	Name	Attention
1	Atrium Therapeutics, Inc.RNA	0%0
2	PepGen Inc.PEPG	0%new
3	Crinetics Pharmaceuticals IncCRNX	0%new
4	Vera Therapeutics Inc.VERA	0%new
5	Cricut, Inc.CRCT	0%0
6	Edgewise Therapeutics Inc.EWTX	0%new
7	uniQure N.V.QURE	0.02%+0.01
8	CNTA - Centessa Pharmaceuticals plc	——
9	Immunovant Inc.IMVT	0%0
10	INZY - Inozyme Pharma, Inc.	——

Dyne Therapeutics, Inc.

Healthcare
Biotechnology

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for genetically driven neuromuscular diseases. Dyne Therapeutics advances a pipeline of investigational medicines designed to deliver treatment directly to muscle tissue and, in some programs, the central nervous system through its proprietary FORCE platform. Its current programs address conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease, along with other rare skeletal, cardiac, and metabolic muscle disorders. The company’s work centers on disease-modifying approaches aimed at the underlying genetic causes of these conditions, positioning it as a specialized player in rare disease drug development. Dyne Therapeutics is headquartered in Waltham, Massachusetts.

Website

Location

1560 Trapelo Road

Waltham, MA, 02451

United States

Social

What share of all stock conversation is about DYN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Sep 9

Dyne Therapeutics' (DYN) stock fell 16% after Novartis' del-desiran failed to meet its primary endpoint in a Phase 3 trial for myotonic dystrophy type 1 (DM1).
The failure raises questions about the clinical efficacy of DYN's z-basivarsen, which uses a similar RNA-targeting approach.
Analysts have maintained their buy ratings for DYN, with some even seeing the drop as an opportunity, citing its upcoming PDUFA date on January 21, 2027, for its BLA in exon 51 DMD.

Generated by AI

Sentiment

Of the messages about DYN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	17.36%	81.95% +7.34
Bearish	0%	0%	82.64%	18.05% -7.34

Bullish· Mar 10

$DYN's positive 24-month cardiopulmonary data from the DELIVER trial reinforces its efficacy and safety profile, and the initiation of the Phase 3 HARMONIA trial is a significant step toward confirmatory approval.
The initiation of the Phase 3 HARMONIA trial for Myotonic Dystrophy Type 1 could push $DYN's price above $20, with a target price of $36-$39.
$DYN's breakout on price and OBV after announcing the initiation of the Phase 3 trial for Myotonic Dystrophy Type 1 is a strong indication of active repositioning and could lead to a crowded trade if the breakout confirms.

Bearish· Sep 3

$DYN's poor Phase 1/2 results led to a 30% stock price drop, and the company's lack of annual revenue raises concerns about the drug's viability.
The company's management team change and recent insider selling activity, including the Board and senior management selling shares in August, may indicate that the results were worse than expected.
$DYN's stock price has been volatile, with a significant decline, and some investors are questioning whether the price will continue to fall, potentially reaching single digits by the end of the year.

Generated by AI

Topics

Of the messages about DYN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	11.72%	77.93%
Technical Analysis	100%	100%	1.67%	3.62%
Analysts	0%	0%	43.51%	12%
Controversies	0%	0%	0%	0.14%
Macro	0%	0%	43.1%	6.31%
Earnings	0%	0%	0%	0%

Earnings· Nov 1

$DYN misses Estimize EPS consensus by 26c and beats revenue consensus by $32.26M.
$DYN reports FQ3 earnings of 23c EPS and $1.44B Revs.
$DYN reports Q3 EPS loss of $0.89, missing consensus by $0.29.

Announcements· Dec 8

Dyne Therapeutics ($DYN) plans to file for approval for a next-generation Duchenne drug, potentially a more effective version of Sarepta's Exondys.
The company announced positive topline results from the Phase 1/2 DELIVER trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD).
Dyne Therapeutics has announced a proposed public offering of common stock, with the company planning to sell $300 million worth of new shares.

Technical Analysis· Jan 3

$DYN has reached an all-time high (ATH) and is approaching it, with a target above $30.
A trend line on $DYN is cracking, indicating a potential short opportunity, with possible targets at $25-26 and $29-30.
$DYN's price action is showing a possible short setup below $17.5, with a potential long opportunity above $24.00, and a low float of 31.4 million shares.

Generated by AI

Community

Of the messages about DYN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	17.03%	50.83%
Newcomers	100%	100%	82.97%	49.17%

Regulars· Sep 8

The main topic of discussion among regulars is the efficacy of Dyne Therapeutics' (DYN) z-basivarsen in correcting DM1 by reducing toxic DMPK RNA, with some comparing it to a rival drug from Spark Therapeutics (SRPT).
Regulars are closely following the upcoming milestones for DYN, including the PDUFA date for z-rostudirsen in DMD, the potential submission for US approval of z-basivarsen, and the expected launch of z-rostudirsen in the US.
The recent sell-off of DYN stock is attributed to the failure of a rival drug, and regulars are debating the potential for DYN to overcome the challenges of dosing high enough to achieve significant knockdown of DMPK RNA.

Newcomers· Sep 8

New investors are focusing on the potential of Dyne Therapeutics, Inc. (DYN) as a treatment option, specifically the operating mechanism of its ASOs in the nucleus compared to other treatments.
Some newcomers are trying to gauge the market's sentiment towards DYN, comparing its performance to that of another company, Spark Therapeutics (SRPT), and looking for specific price levels to be reached in order to re-rate the stock.
A few newcomers are looking for news or explanations behind the recent price drop of DYN, with some questioning the reason behind the 30% decline and others expressing skepticism or frustration.

Generated by AI

Dyne Therapeutics

Social

Sep 9

Bullish· Mar 10

Bearish· Sep 3

Earnings· Nov 1

Announcements· Dec 8

Technical Analysis· Jan 3

Regulars· Sep 8

Newcomers· Sep 8

Dyne Therapeutics stock rises on positive DM1 trial results

Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?

Dyne Therapeutics at Morgan Stanley conference: launch plans take focus

Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)

Also Discussed

Dyne Therapeutics, Inc.

Company Information

Location

Dyne Therapeutics stock rises on positive DM1 trial results

Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?

Dyne Therapeutics at Morgan Stanley conference: launch plans take focus

Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN)

Also Discussed

Social

Sep 9

Bullish· Mar 10

Bearish· Sep 3

Earnings· Nov 1

Announcements· Dec 8

Technical Analysis· Jan 3

Regulars· Sep 8

Newcomers· Sep 8